The Procter & Gamble Company has entered a definitive agreement to acquire the dietary supplement manufacturer Thorne. This move signals a significant push by the consumer goods giant into the premium wellness sector. The acquisition involves the transfer of Thorne from L Catterton’s Flagship Fund to P&G.
Industry analysts value the transaction at approximately $3.8 billion. Thorne has established a reputation for its science-based supplement line, which appeals to consumers looking for health solutions beyond traditional offerings. By bringing Thorne under its corporate structure, P&G gains a foothold in a specialized market that prioritizes clinical validation and personalized health products.
Colin Watts, the CEO of Thorne, stated that the company views P&G as the right partner to help expand its market presence. He emphasized that the deal allows Thorne to maintain its established product standards and core values while reaching a broader audience. This transition marks a notable shift in the wellness space as large conglomerates look for proven brands to bolster their portfolios.
For P&G, the acquisition is part of a broader strategy to address consumer demand for high-end wellness. The company aims to integrate Thorne’s operations into its existing model. This move reflects the ongoing trend where major manufacturers seek to acquire established, evidence-focused brands to secure a competitive advantage in the health and supplement industry.